At the news
? NEUTRALIMPACT 3/10 144 filed Jun 22, 2026 at 16:49 ET
CG Oncology director Leonard Post filed a Form 144 indicating intent to sell 6,000 shares (~$366K) under a 10b5-1 plan, likely to exercise stock options. The sale is small relative to market cap ($5.4B) and pre-planned, carrying minimal signal.
- Insider: Leonard E. Post, Director
- Shares to sell: 6,000 common shares
- Estimated value: $366,480 (based on $61.08/share)
- Sale method: Morgan Stanley Smith Barney, pre-arranged 10b5-1 plan
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access